drugset / Trial / NCT00835705

Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditions

NCT00835705

Phase 1 Completed 52 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study is to compare the rate and extent of absorption of amoxicillin-clavulanic acid 400 mg-57 mg chewable tablets (test) versus Augmentin® (reference) administered as 1 x 400 mg-57 mg chewable tablet under fasting conditions.

Timeline

Start
2003-09
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 57 mg
Subject Amoxicillin Other / unclassified 400 mg

Indications

No indication recorded.